Recovery of viable Chlamydia pneumoniae from atheromas of coronary heart diseases
patients has initiated pilot studies to eradicate C. pneumoniae from vascular tissue by …

Chlamydia pneumoniae may modulate the proliferation of smooth muscle cells (SMC) in
atherosclerotic plaques. Conditioned medium from C. pneumoniae-infected SMC decreased …

Background Definitive fate of the coronary endothelium after implantation of a drug-eluting
stent remains unclear, but evidence has accumulated that treatment with rapamycin-eluting …

Mattila KJ, Juvonen JT, Kotamäki MK, Saikku PA (Helsinki University Hospital, Helsinki;
Kainuu Central Hospital, Kajaani, and National Public Health Institute, Oulu, Finland) …

Objectives: The aim of this study was to assess the role of short oral administration of
rapamycin, without loading dose, in the reduction of restenosis rate after bare metal stent …

The strength of the epidemiologic and clinical associations of Chlamydia pneumoniae with
atherosclerosis can be increased by the demonstration that C pneumoniae can initiate and …

Chlamydia pneumoniae may play a role in atherogenesis and vascular diseases, and
antibiotics may prove useful in these conditions. Three groups of New Zealand White rabbits …

In contrast to several previously published studies, 1–3 the one by Caligiuri et al4 failed to
observe an accelerating effect of Chlamydia pneumoniae infection on atherosclerotic lesion …

Chlamydia pneumoniaeis a Gram-negative obligate intracellular bacterium that causes
acute upper and lower respiratory infections. Its distribution is worldwide …

Restenosis after percutaneous transluminal coronary angioplasty or directional coronary
atherectomy is a major limitation to long-term benefit; it is, however, a complex process that …